The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin

The oxazolidinones are a novel class of antibiotics that act by inhibiting protein synthesis. It as been reported that the drug exerts its primary activity on the initiation phase of translation. In order to study the possibility of direct interaction between the drug and the ribosome, we have developed a binding assay using C-14-labelled eperezolid (PNU-100592; formerly U-100592), Eperezolid binds specifically to the 50S ribosomal subunit of Escherichia coli, The specific binding of eperezolid is dose dependent and is proportional to the ribosome concentrations, Scatchard analysis of the binding data reveals that the dissociation constant (K-d) is about 20 mu M. The binding of eperezolid to the ribosome is competitively inhibited by chloramphenicol and lincomycin. However, unlike chloramphenicol and lincomycin, eperezolid does not inhibit the puromycin reaction, indicating that the oxazolidinones have no effect on peptidyl transferase, In addition, whereas lincomycin and, to some extent, chloramphenicol inhibit translation termination, eperezolid has no effect, Therefore, we conclude that the oxazolidinones inhibit protein synthesis by binding to the 50S ribosomal subunit at a site close to the site(s) to which chloramphenicol and lincomycin bind but that the oxazolidinones are mechanistically distinct from these two antibiotics.